Keywords: avonex, sales, disappoint, usa, according, analysts, biogen
Avonex sales disappoint in USA, according to analysts
Article | 11 October 2000
Biogen has reported lower-than-expected US sales of its flagshipmultiple sclerosis treatment Avonex (interferon beta-1a) owing to what analysts described ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
